A Narrative Review and Risk-Stratification Framework for Preventing LNG-IUS Expulsion in Adenomyosis.

IF 2.6 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics
Therapeutics and Clinical Risk Management Pub Date : 2026-01-08 eCollection Date: 2026-01-01 DOI:10.2147/TCRM.S566786
Jin Zhao, Jianliang Chen, Xiaoe Wang, Huabin Wang
{"title":"A Narrative Review and Risk-Stratification Framework for Preventing LNG-IUS Expulsion in Adenomyosis.","authors":"Jin Zhao, Jianliang Chen, Xiaoe Wang, Huabin Wang","doi":"10.2147/TCRM.S566786","DOIUrl":null,"url":null,"abstract":"<p><p>Levonorgestrel-releasing intrauterine system (LNG-IUS) expulsion rates are markedly elevated (15-37.5%) in patients with adenomyosis compared to those with normal uteri (3-10%), significantly compromising treatment efficacy and adherence. Existing evidence on risk factor mitigation is fragmented, lacking a structured management framework. This narrative review synthesizes current literature to identify key determinants of expulsion-including uterine enlargement, intracavitary lesions, and insertion techniques-and evaluates preventive strategies such as GnRH-agonist pretreatment and imaging-guided placement. Its primary aim is to propose a novel, three-tiered risk-stratification model that tailors management (conventional, augmented, or advanced fixation approaches) to individual patient profiles based on anatomical, procedural, and clinical factors. This structured approach seeks to optimize LNG-IUS retention and resource allocation. Prospective validation through randomized controlled trials remains essential to establish evidence-based, personalized protocols.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"22 ","pages":"566786"},"PeriodicalIF":2.6000,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12998664/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S566786","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Levonorgestrel-releasing intrauterine system (LNG-IUS) expulsion rates are markedly elevated (15-37.5%) in patients with adenomyosis compared to those with normal uteri (3-10%), significantly compromising treatment efficacy and adherence. Existing evidence on risk factor mitigation is fragmented, lacking a structured management framework. This narrative review synthesizes current literature to identify key determinants of expulsion-including uterine enlargement, intracavitary lesions, and insertion techniques-and evaluates preventive strategies such as GnRH-agonist pretreatment and imaging-guided placement. Its primary aim is to propose a novel, three-tiered risk-stratification model that tailors management (conventional, augmented, or advanced fixation approaches) to individual patient profiles based on anatomical, procedural, and clinical factors. This structured approach seeks to optimize LNG-IUS retention and resource allocation. Prospective validation through randomized controlled trials remains essential to establish evidence-based, personalized protocols.

Abstract Image

Abstract Image

2010年防止LNG-IUS驱逐的叙事回顾和风险分层框架。
与子宫正常的患者(3-10%)相比,子宫腺肌症患者的左炔诺孕酮释放宫内系统(LNG-IUS)排出率显著升高(15-37.5%),显著影响治疗效果和依从性。关于减轻风险因素的现有证据支离破碎,缺乏结构化的管理框架。这篇综述综合了目前的文献,以确定子宫排出的关键决定因素,包括子宫增大、腔内病变和插入技术,并评估了预防策略,如gnrh激动剂预处理和成像引导放置。其主要目的是提出一种新颖的三层风险分层模型,根据解剖、手术和临床因素为个体患者量身定制管理(传统、增强或先进的固定方法)。这种结构化方法旨在优化LNG-IUS的保留和资源分配。通过随机对照试验进行前瞻性验证对于建立基于证据的个性化方案至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-
CiteScore
5.30
自引率
3.60%
发文量
139
审稿时长
16 weeks
期刊介绍: Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书